Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : American Bio Medica (ABMC) drug test solution -taking off! -- Ignore unavailable to you. Want to Upgrade?

To: Mr. E who wrote (535)	7/12/1999 6:51:00 PM
From: Mr. E	Respond to of 629

American Bio Medica Posts Fourth Quarter Sales Increase and Initiates Cost-Cutting Program to Improve Earnings Business Wire - July 01, 1999 08:47 HUDSON, N.Y.--(BUSINESS WIRE)--July 1, 1999--American Bio Medica Corp. (NASDAQ: ABMC) today reported a 170% rise in fourth quarter fiscal 1999 sales. The Company also said it undertook several restructuring initiatives to reduce expenses in various business areas, improve operating efficiencies, and increase earnings. "We are successfully creating a leaner, more efficient business through a multi-thrust campaign to reduce expenses and improve sales and marketing operations in order to boost both sales and earnings," said ABMC President and CEO Stan Cipkowski. To improve the return on sales and marketing expenditures, ABMC said it reduced and reorganized the sales and marketing team and will relocate the Florida sales and marketing office to the New York headquarters on September 1, 1999. The Company also said it has trimmed its conference schedule to maximize sales impact and refocused marketing efforts on the most dynamic sectors of the drug testing industry. The Company expects to reduce the cost of goods in the current fiscal year by initiating in-house manufacturing of certain critical raw materials. ABMC also reported that its 10-K Annual Report should be filed on time with the Company's complete audited statements. Sales for the fourth quarter fiscal 1999 were $1,930,000 as compared to $714,000 in the same period last year. "The fact that we generated relatively steady quarter to quarter revenues was expected due to the cyclical and seasonal factors that were anticipated this year in the various market segments where we operate," Cipkowski commented. "While we generated continued expansion in most of the sectors that we sell to, we are experiencing extraordinary growth in some of our markets and working to increase sales into other segments where we see significant potential to capture solid market share." American Bio Medica Corporation develops, manufactures and markets inexpensive, accurate, on-site drugs of abuse diagnostic kits and support services worldwide. The Company's global distributors target the workplace, clinical, rehabilitation, physicians, corrections, and educational markets. ABMC's Rapid Drug Screen is proven to correlate 100% with the standard laboratory screening test. Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risk and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, intellectual property rights, and other risks detailed from time to time in the Company's periodic report filed with the Securities and Exchange Commission. CONTACT: American Bio Medica Corp. Stan Cipkowski, President & CEO or Melissa Decker, Investor Relations Manager 800/227-1243 Fax: 518/822-0391 abmc@taconic.net www.americanbiomedica.com

To: Mr. E who wrote (535)	7/12/1999 6:52:00 PM
From: Mr. E	Read Replies (1) \| Respond to of 629

American Bio Medica Launches One of the Industry's Most Extensive National Collection Networks With Western Pathology Consultants Business Wire - July 08, 1999 08:46 HUDSON, N.Y.--(BUSINESS WIRE)--July 8, 1999--American Bio Medica Corp. (NASDAQ: ABMC) today announced its affiliation with Western Pathology Consultants, Inc. (WPCI) to provide a total drug testing program that combines a national network of collection centers performing ABMC's Rapid Drug Screen(TM) with a broad range of value-added services. ABMC and WPCI's national network is one of the largest in the drug testing industry. It presently includes 1,650 locations and 900 mobile collectors; the latter perform the Rapid Drug Screen on-site and are especially useful for random screening programs. An additional 2,000 centers are being brought on board over the next 6 to 9 months in order to further expand the network. ABMC will now move forward with an aggressive sales and marketing program for high volume testers that, to date, have for the most part remained with laboratories and third-party administrators. The new national network affiliation between ABMC and WPCI allows both organizations to capture the high volume market segment without incurring any additional expenses. "American Bio Medica is once again at the forefront of industry innovation with a complete program that meets significant demand from our customers and distributors," said ABMC President and CEO Stan Cipkowski. "By providing qualified professionals to conduct the tests, lab confirmations of positive screens, and Medical Review Officers to review the positive results, we are confident the program will dramatically increase our market share and positively impact our bottom line." The national collection network encompasses quality control, chain of custody documentation, SAMHSA laboratory confirmation of positive screens, Medical Review Officer (MRO) review of laboratory positives, and summary reports. Since it is offered for a fixed per test charge, the service will enable companies to better budget their substance abuse testing initiatives. American Bio Medica Corporation develops, manufactures and markets inexpensive, accurate, on-site drugs of abuse diagnostic kits and support services worldwide. The Company's global distributors target the workplace, clinical, rehabilitation, physicians, corrections, and educational markets. ABMC's Rapid Drug Screen is proven to correlate 100% with the standard laboratory screening test. Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risk and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, intellectual property rights, and other risks detailed from time to time in the Company's periodic report filed with the Securities and Exchange Commission. CONTACT: American Bio Medica Corp. Stan Cipkowski, President & CEO Melissa Decker, Investor Relations Manager Tel: 800/227-1243 Fax: 518/822-0391 Email: abmc@taconic.net www.americanbiomedica.com